XML 48 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Statements of Cash Flows (Unaudited) (USD $)
6 Months Ended
Mar. 31, 2015
Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES    
Net Income (loss) $ (10,236,365)us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet $ (1,450,443)us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
Adjustments to reconcile net Income to net cash (used in) provided by operating activities:    
Stock issued for services rendered by consultants    380us-gaap_StockIssuedDuringPeriodValueIssuedForServices
Stock issued for interest    3,570BMSN_StockIssuedDuringPeriodValueIssuedForInterest
Stock issued for expenses    48,000BMSN_StockIssuedForExpenses
Interest Expense attributable to amortization of discount 4,032us-gaap_InterestExpenseOther   
Changes in operating assets and liabilities:    
(Increase) Decrease in Prepaid Expenses      
Increase (Decrease) in Accounts Payable 187us-gaap_IncreaseDecreaseInAccountsPayable 4,999us-gaap_IncreaseDecreaseInAccountsPayable
Increase (Decrease) in Accrued Expenses 107,362us-gaap_IncreaseDecreaseInAccruedLiabilities (92,111)us-gaap_IncreaseDecreaseInAccruedLiabilities
Increase (Decrease) in bank Overdraft (6,137)us-gaap_ProceedsFromRepaymentsOfBankOverdrafts 801us-gaap_ProceedsFromRepaymentsOfBankOverdrafts
(Increase) Decrease in Interest Receivable (551)us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable   
Increase (Decrease) in Due to Affiliate    (28,117)us-gaap_IncreaseDecreaseInDueToAffiliates
(Increase) Decrease in Note Receivable (1,629)us-gaap_IncreaseDecreaseInNotesReceivables   
Net Cash Provided by (Used in) Operating Activities (10,133,101)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (1,512,921)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
CASH FLOWS FROM FINANCING ACTIVITIES    
Additional paid in Capital 433,345us-gaap_AdjustmentsToAdditionalPaidInCapitalOther 300,000us-gaap_AdjustmentsToAdditionalPaidInCapitalOther
Increase (Decrease) in due to subsidiary shareholder      
Principal borrowings (repayments) on notes and Convertible Debentures 90,453us-gaap_RepaymentsOfConvertibleDebt 234,266us-gaap_RepaymentsOfConvertibleDebt
Principal borrowings (repayments) on Convertible Debentures 1,182,686BMSN_RepaymentsOfConvertibleDebt1   
Loss on Settlement of Debt through Equity Issuance 9,015,962us-gaap_NondebtorReorganizationItemsNetGainLossOnSettlementOfOtherClaims1 984,730us-gaap_NondebtorReorganizationItemsNetGainLossOnSettlementOfOtherClaims1
Net Cash Provided by (Used in) Financing Activities 10,722,446us-gaap_NetCashProvidedByUsedInFinancingActivities 1,518,996us-gaap_NetCashProvidedByUsedInFinancingActivities
Net Increase (Decrease) in Cash 589,345us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 6,075us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash at Beginning of Period 502BMSN_CashAtBeginningOfPeriod 116,714BMSN_CashAtBeginningOfPeriod
Cash at End of Period 589,847us-gaap_CashAndCashEquivalentsAtCarryingValue 122,789us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental Disclosure of Noncash investing and financing activities:    
Common Shares Issued for Debt 37,000us-gaap_StockIssued1 83,000us-gaap_StockIssued1
Common Shares of Regen Biopharma, Inc. Issued for Debt $ 882,686BMSN_CommonSharesOfSubsidiaryIssuedForDebt